StockData
Palvella Therapeutics, Inc. logo

Palvella Therapeutics, Inc. (PVLA) stock

PVLANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$144.35−0.25 (-0.17%)

Close on Nov 17, 2026Market cap $2.08BP/E –Yield –

Palvella Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Palvella Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $35.46M, up 137.7% year over year. For fiscal 2025 it was $22.84M, up 180.2% from the year before. Over ten years it grew 10.7% a year on average. The highest annual figure on record is $66.66M in fiscal 2021.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$22.84M+180.2%
FY2024Dec 31, 2024$8.15M-7.3%
FY2023Dec 31, 2023$8.79M-83.4%
FY2022Dec 31, 2022$52.98M-20.5%
FY2021Dec 31, 2021$66.66M+43.3%
FY2020Dec 31, 2020$46.53M-15.4%
FY2019Dec 31, 2019$55.00M+32.6%
FY2018Dec 31, 2018$41.49M+86.2%
FY2017Dec 31, 2017$22.29M+13.1%
FY2016Dec 31, 2016$19.70M+138.9%
FY2015Dec 31, 2015$8.24M+47.2%
FY2014Dec 31, 2014$5.60M-40.5%
FY2013Dec 31, 2013$9.41M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$12.47M+143.7%
Q1 FY2026Mar 31, 2026$9.33M+129.1%
Q4 FY2025Dec 31, 2025$7.12M+180.0%
Q3 FY2025Sep 30, 2025$6.53M+105.2%
Q2 FY2025Jun 30, 2025$5.12M+254.9%
Q1 FY2025Mar 31, 2025$4.07M+314.0%
Q4 FY2024Dec 31, 2024$2.54M-42.9%
Q3 FY2024Sep 30, 2024$3.18M-66.8%
Q2 FY2024Jun 30, 2024$1.44M-89.9%
Q1 FY2024Mar 31, 2024$984.00K-92.7%
Q4 FY2023Dec 31, 2023$4.45M-66.7%
Q3 FY2023Sep 30, 2023$9.60M-29.4%
Q2 FY2023Jun 30, 2023$14.33M+19.9%
Q1 FY2023Mar 31, 2023$13.42M-4.6%
Q4 FY2022Dec 31, 2022$13.38M-12.9%
Q3 FY2022Sep 30, 2022$13.59M-28.2%
Q2 FY2022Jun 30, 2022$11.95M-24.4%
Q1 FY2022Mar 31, 2022$14.07M-15.1%
Q4 FY2021Dec 31, 2021$15.36M+44.6%
Q3 FY2021Sep 30, 2021$18.94M+60.2%
Q2 FY2021Jun 30, 2021$15.80M+39.4%
Q1 FY2021Mar 31, 2021$16.56M+29.8%
Q4 FY2020Dec 31, 2020$10.62M-24.8%
Q3 FY2020Sep 30, 2020$11.82M-10.5%
Q2 FY2020Jun 30, 2020$11.33M-15.3%
Q1 FY2020Mar 31, 2020$12.76M-10.8%
Q4 FY2019Dec 31, 2019$14.12M+8.6%
Q3 FY2019Sep 30, 2019$13.21M+15.9%
Q2 FY2019Jun 30, 2019$13.37M+46.1%
Q1 FY2019Mar 31, 2019$14.30M+80.1%
Q4 FY2018Dec 31, 2018$13.00M+146.6%
Q3 FY2018Sep 30, 2018$11.40M+82.2%
Q2 FY2018Jun 30, 2018$9.16M+69.7%
Q1 FY2018Mar 31, 2018$7.94M+48.1%
Q4 FY2017Dec 31, 2017$5.27M-23.8%
Q3 FY2017Sep 30, 2017$6.26M+35.4%
Q2 FY2017Jun 30, 2017$5.40M–
Q1 FY2017Mar 31, 2017$5.36M–
Q4 FY2016Dec 31, 2016$6.92M–
Q3 FY2016Sep 30, 2016$4.62M–

More Palvella Therapeutics figures

See a number that looks wrong?